Showing 4321-4330 of 5771 results for "".
- Optomed Establishes a Scientific Advisory Boardhttps://modernod.com/news/optomed-establishes-a-scientific-advisory-board/2478806/Optomed announced it is establishing an international scientific advisory board consisting of globally recognized and scientifically merited medical doctors specializing in ophthalmology and neuro-ophthalmology, with advanced experience on artificial intelligence applied to detection of ophthalmi
- Neurophth Therapeutics Appoints Qiutang Li, PhD, as Chief Scientific Officerhttps://modernod.com/news/neurophth-therapeutics-appoints-qiutang-li-phd-as-chief-scientific-officer/2478800/Wuhan Neurophth Biotechnology, a developer of AAV-delivered gene therapies for the treatment of ocular diseases, announced the appointment of Qiutang Li, PhD, as Chief Scientific Officer. She will be mainly responsible for the company’s global R&D, IND portfolio strategy, and the establ
- Google Commits $150M to COVID-19 Vaccine Education, Partnering With One Medical to Open Vaccination Siteshttps://modernod.com/news/google-commits-150m-to-covid-19-vaccine-education-partnering-with-one-medical-to-open-vaccination-sites/2478801/Google is committing $150 million to promote COVID-19 vaccine education and equitable distribution to underserved communities, the tech giant announced Monday, as
- Elizabeth Yeu, MD, and K. Peony Yu, MD, Appointed to Staar Surgical Board of Directorshttps://modernod.com/news/elizabeth-yeu-md-and-k-peony-yu-md-appointed-to-staar-surgical-board-of-directors/2478798/Staar Surgical announced the appointments of Elizabeth Yeu, MD, Partner, Virginia Eye Consultants, and K. Peony Yu, MD, retired Chief Medical Officer, FibroGen, to its Board of Directors, effective January 21, 2021. “The addition of Dr. Elizabeth Yeu and Dr. K. Peony Yu to our Board of Dir
- Zenni Releases New Anti-Fog Glasses Lenses to Address Mask-Related Fogginghttps://modernod.com/news/zenni-releases-new-anti-fog-glasses-lenses-to-address-mask-related-fogging/2478797/Zenni announced a 2-in-1 anti-fog + anti-reflective lens solution to solve a pain point for glasses wearers during the pandemic. Developed in 2020 as a response to the pervasive consumer issue of glasses fogging up while wearing face coverings, these new anti-fog coated lenses are the only low pr
- Genentech’s Faricimab Meets Primary Endpoint in Two Global Phase 3 Studies in Wet AMDhttps://modernod.com/news/genentechs-faricimab-meets-primary-endpoint-in-two-global-phase-3-studies-in-wet-amd/2478792/Genentech announced positive topline results from two identically designed global phase 3 studies, TENAYA and LUCERNE, evaluating its investigational bispecific antibody, faricimab, in people living with wet age-related macular degeneration (AMD). Both studies met their primary endpoint and showe
- Ace Vision Group Closes Series A Stock Round to Advance Ophthalmic Technologieshttps://modernod.com/news/ace-vision-group-closes-series-a-stock-round-to-advance-ophthalmic-technologies/2478790/Ace Vision Group announced that it closed a Series A preferred stock round totaling $13.3 million ($3.3 million oversubscribed) to continue development and commercialization of its VisioLite Ophthalmic Laser, a touchless therapeutic device being developed for the treatment of age-related vision d
- Eyedaptic Augmented Reality Visual Aid Granted Patent to Further Aid Those With Macular Degeneration and Low Visionhttps://modernod.com/news/eyedaptic-augmented-reality-visual-aid-granted-patent-to-further-aid-those-with-macular-degeneration-and-low-vision/2478789/Eyedaptic announced it was recently granted the first out of nine pending patents. Additionally, Eyedaptic launched an Equity Crowdfunding Campaign to increase awareness and introduce their advanced visual aid solution to an expanding list of stakeholders in the eye care and technology communitie
- Lilly’s Bamlanivimab Cuts Risk of COVID-19 By Up to 80% at Nursing Homeshttps://modernod.com/news/lillys-bamlanivimab-cuts-risk-of-covid-19-by-up-to-80-at-nursing-homes/2478788/Eli Lilly announced Thursday that in a phase 3 study, bamlanivimab was shown to significantly reduce the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities. The findings from the BLAZE-2 COVID-19 prevention trial suggest the risk was decreased by up to
- Keeler Partners With Merakris Therapeutics, Developer of Biological Barrier Grafthttps://modernod.com/news/keeler-patners-with-merakris-therapeutics-developer-of-biological-barrier-graft/2478785/Keeler has announced its partnership with Merakris Therapeutics, which is developing commercially scalable biotherapeutic technologies derived from stem cells that promote homeostasis in damaged tissue. Terms of the deal were not disclosed. “We are excited. This partnership accelera